ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

The ALS Curveball

New York, United States - 09-12-2022 (PR Distribution™) -

A Short History

The 19th century was a period marked by an explosion of medical advances.  Vaccines emerged to protect from infectious disease, anesthesia numbed surgical patients and medical imaging used X-rays to improve diagnosis among other examples of progress.  This was also the period when physicians began to empirically analyze and differentiate diseases.  Smallpox, typhus, yellow fever and scarlet fever were common maladies of the time, with large public efforts emerging against them.  Rare diseases, however, received less attention, but detail-oriented physicians began to catalog these orphan conditions.  One disease in particular that caught the eye of many distinguished scientists was amyotrophic lateral sclerosis (ALS).

9282374-1

A description of ALS was first recorded in 1824 when Scottish surgeon Charles Bell observed and described the symptoms[i] of a motor neuron disease without identifying it.  Others, including French physician François-Amilcar Aran in 1850[ii], Jean Cruveilhier in 1853, and Augustus Jacob Lockhart Clarke in 1860[iii] also noted similar descriptions and conducted studies in patients with symptoms matching that of ALS.

The individual most closely associated with ALS research is Jean-Martin Charcot, a French neurologist who is known as the founder of modern neurology.  He made substantial strides in understanding Parkinson’s disease and contributed to the base of knowledge in other areas of neurology including multiple sclerosis, post-traumatic stress disorder and other diseases.  In ALS, he was the first to connect clinical symptoms to the pathology seen at autopsy.  Charcot detailed the symptoms of ALS noting isolated progressive motor symptoms with fasciculation, contractures, bulbar involvement and death from respiratory failure.  He termed the disease ‘la sclérose amyotrophique’ or amyotrophic lateral sclerosis in English translation. 

9282374-2
Painting of Jean-Martin Charcot Demonstrating Hypnosis. Une leçon clinique à la Salpêtrière by André Brouillet. Wikimedia Commons [iv].

Further advances in ALS were made by Dr. William Osler who recognized a succession of Familiar ALS in the late 19th century.  Dr. Osler conducted his work following the history of the Farr family of Vermont where he found 14 clan members that died at an early age presenting symptoms of ALS.  In 1880, Dr. William Osler published a medical paper identifying ALS in its hereditary form.  The work entitled “Heredity in Progressive Muscular Atrophy as Illustrated in the Farr Family of Vermont” identified several members of the Farr family that had died young from a muscle wasting disease over multiple generations.  Later descendants died of the same disease guiding subsequent research to conduct genetic tests when the technology was available.  This led to the identification of mutations in the SOD1 gene in 1993 that were associated with the illness.

In the years after World War II, scientists observed an ALS cluster in Guam.  During this period there was a surprising emergence of numerous cases in the local Chamorro population on the island at a 50 to 100-fold greater incidence than in the United States.  The rise in cases was attributed to increased consumption of food sources that were used as an alternative during war-related shortages.[v]  The seeds contained a neurotoxin that is associated with neurodegenerative disease.

The type of ALS specific to Guam is called amyotrophic lateral sclerosis-Parkinsonism dementia complex, or ALS-PDC.  The increase in ALS-PDC in the area was attributed to consumption of the seeds of the cycad plant.  The flour from these seeds contains many water-insoluble neurotoxic agents.  The most neurologically damaging of these is beta-sitosterol beta-D-glucoside (BSSG) which is implicated in ALS-PDC.[vi]  BSSG was also shown to induce hyperphosphorylated tau expression in neurons, a hallmark of Alzheimer’s disease and related tauopathies. Further, Guiroy et al.[vii] found that the amyloid of neurofibrillary tangles of Guamanian parkinsonism-dementia has an identical amino acid sequence to that of Alzheimer disease and Down syndrome, providing a link among the neurodegenerative diseases.

ALS in Popular Culture

Being a rare disease, ALS did not receive much attention from the general population in the United States until the late 1930s.  It was in 1939 when one of the most popular sports figures of the day, Lou Gehrig of the New York Yankees, was thrown a curveball and diagnosed with the disease. Lou played 17 seasons with the team and broke numerous records.  In his last year, he suffered physical changes which led to a decline in his performance and eventual diagnosis at the Mayo Clinic in Rochester, Minnesota.  After an inspiring speech which coincided with his retirement, Lou died two years later.  This event led to broad recognition of the disease outside of the medical community for the first time and led to the it being commonly labeled Lou Gehrig’s disease in the United States.   

9282374-3
Lou Gehrig of the New York Yankees. cropped from a posed picture of 1937 Major League Baseball All-Stars in Washington, DC. [viii]

In the last decade, the focus on ALS has centered around a few individuals and events.  One of the more prominent was the physicist Stephen Hawking, who is best known for his theories on relativity and quantum mechanics. He lived with the early onset, slow progressing form of ALS for over 50 years and during that time was a prolific author, researcher, professor and subject of a popular 2014 movie. 

A recent campaign that ushered this rare disease to the forefront was the Ice Bucket Challenge. It was a popular phenomenon that brought politicians, actors and other well-known figures to social media to draw attention to ALS and raise funding to support research.  Emerging in 2014, reaching a crescendo the following year and continuing on for several years after, the effort raised over $220 million around the world.  The Ice Bucket Challenge was a success and attracted more attention to ALS while providing funds for identifying new genes connected to ALS, research grants, and expansion of the network of scientists working on treatments and a cure. 

What’s Next?

The recorded history of ALS extends back almost two centuries and in prominently visible despite addressing a rare disease.  The distinguished physicians who have investigated the disorder and the renowned figures who have accomplished great things in spite of ALS illuminate the human side of this neurodegenerative malady, setting the stage for further investigative work.  In our next segment of the ALS Curveball series, we will explain the features, examine the types and establish the prevalence of ALS.

Please visit our website at unboxingbiotech.com for other articles in this series.  

Follow us on our YouTube channel: Unboxing Biotech.

Endnotes:

[i] https://www.hopkinsmedicine.org/news/publications/hopkins_medicine_magazine/features/winter-2016/an-answer-to-als

[ii] https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(15)00308-7/fulltext

[iii] https://academic.oup.com/brain/article/133/11/3470/310899

[iv] Photo of an oil painting. Une leçon clinique à la Salpêtrière by André Brouillet. Wikimedia Commons.

[v] Kurland, L., Mulder, D. Epidemiologic investigations of amyotrophic lateral sclerosis. I. Preliminary report on geographic distribution, with special reference to the Mariana Islands, including clinical and pathologic observations. Neurology. 1954 May;4(5):355-78. doi: 10.1212/wnl.4.5.355.

[vi] Van Kampen, JM, Robertson, HA. The BSSG Rat Model of Parkinson’s Disease: Progressing Towards A Valid, Predictive Model of Disease. EPMA Journal (2017) 8:261–271  DOI 10.1007/s13167-017-0114-6

[vii] Guiroy, D. C., Miyazaki, M., Multhaup, G., Fischer, P., Garruto, R. M., Beyreuther, K., Masters, C. L., Simms, G., Gibbs, C. J., Jr., Gajdusek, D. C. Amyloid of neurofibrillary tangles of Guamanian parkinsonism-dementia and Alzheimer disease share identical amino acid sequence. Proc. Nat. Acad. Sci. 84: 2073-2077, 1987.

[viii]Lou Gehrig of the New York Yankees, cropped from a posed picture of 1937 Major League Baseball All-Stars in Washington, DC.  This work is from the Harris & Ewing collection at the Library of Congress.

Media Contacts:

Company Name: Unboxing Biotech
Full Name: John Vandermosten
Phone: (240) 778-4204
Email Address: Send Email
Website: http://unboxingbiotech.com

For the original news story, please visit https://www.prdistribution.com/news/the-als-curveball/9282374.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.